The certain uncertainty of measuring disease activity in IBD

Journal of Clinical Gastroenterology

Volumn 41, Issue 2, 2007, Pages 123-125

  Ullman, Thomas A ^a   Palmon, Ron ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE PHASE PROTEIN; ADALIMUMAB; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; OSTEOPONTIN;

BIOLOGICAL THERAPY; BLOOD CELL COUNT; CROHN DISEASE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; EDITORIAL; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; GASTRITIS; HEMATOCRIT; HUMAN; INTESTINE MOTILITY; LEUKOCYTE COUNT; NEUTROPHIL COUNT; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; THROMBOCYTE COUNT; ULCERATIVE COLITIS; VALIDATION PROCESS;

ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; HUMANS; INFLAMMATORY BOWEL DISEASES; OSTEOPONTIN;

EID: 33846407228     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000225660.15556.4e     Document Type: Editorial

References (12)

1. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
2. Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359-367.
3. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol. 2001;96:776-781.
4. Vermeire S, VanAssche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
5. Feagan BG, Rutgeerts P, Schreiber S, et al. Low Baseline CRP Correlates With a High Placebo Remission Rate in Crohn's Disease (CD) Clinical Trial at 12 Weeks. Gastroenterology. 2005;128 (suppl 2):A307.
6. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005;129:807-818.
7. Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut. 2004;53:1485-1493.
8. Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol. 2003;98:1309-1314.
9. Tibble J, Teahon K, Thjodleifsson B, et al. A simple method for assessing intestinal inflammation in Crohn's disease. Gut. 2000;47: 506-513.
10. Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847-853.
11. Mishima R, Takeshima F, Sawai T, et al. High plasma osteopontin levels in patients with ulcerative colitis. J Clin Gastroenterol. 2007; 41:167-172.
12. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ. 1989;298:82-86.